These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 28165905)

  • 1. Reply to C. Buttigliero et al and B. Biswas et al.
    Sun M; Hanna N; Trinh QD; Choueiri TK
    J Clin Oncol; 2017 Apr; 35(11):1266-1267. PubMed ID: 28165905
    [No Abstract]   [Full Text] [Related]  

  • 2. Immediate or Delayed Nephrectomy in Patients With Metastatic Renal Cancer Who Are Receiving Targeted Agents: Is the Analysis at Risk for Guarantee-Time Bias?
    Buttigliero C; Tucci M; Vignani F; Di Maio M
    J Clin Oncol; 2017 Apr; 35(11):1264. PubMed ID: 28165894
    [No Abstract]   [Full Text] [Related]  

  • 3. Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy: Scientifically Relevant or Natural Selection?
    Biswas B; Dabkara D; Ganguly S; Eswaran P; Ghosh J
    J Clin Oncol; 2017 Apr; 35(11):1265-1266. PubMed ID: 28165897
    [No Abstract]   [Full Text] [Related]  

  • 4. Kidney cancer: Cytoreductive nephrectomy improves outcomes in the era of targeted therapy.
    Sidaway P
    Nat Rev Urol; 2016 Aug; 13(8):438. PubMed ID: 27377158
    [No Abstract]   [Full Text] [Related]  

  • 5. Is Underutilization of Cytoreductive Nephrectomy in Patients With Metastatic Renal Cancer Contributing to Inferior Survival?
    Molina AM; Hu J; Nanus DM
    J Clin Oncol; 2016 Sep; 34(27):3235-6. PubMed ID: 27528717
    [No Abstract]   [Full Text] [Related]  

  • 6. [Cytoreduction nephrectomy: No future?].
    Balssa L; Kleinclauss F; Almotlak H; Thiery-Vuillemin A
    Bull Cancer; 2018 Nov; 105(11):981-984. PubMed ID: 30336932
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: Comprehensive Characterization of the Perioperative Morbidity of Cytoreductive Nephrectomy.
    Laguna MP
    J Urol; 2016 Jul; 196(1):57-9. PubMed ID: 27321494
    [No Abstract]   [Full Text] [Related]  

  • 8. Cytoreductive Nephrectomy - Patient Selection Is Key.
    Motzer RJ; Russo P
    N Engl J Med; 2018 Aug; 379(5):481-482. PubMed ID: 29860908
    [No Abstract]   [Full Text] [Related]  

  • 9. Metastatic papillary renal cell carcinoma regression after cytoreductive nephrectomy.
    Williams T; Rodriguez R; Murray K; Kovaleski A; Madan R; Van Veldhuizen P
    Urology; 2015 Feb; 85(2):283-7. PubMed ID: 25623665
    [No Abstract]   [Full Text] [Related]  

  • 10. Role of partial nephrectomy as cytoreduction in the management of metastatic renal cell carcinoma.
    Karam JA; Babaian KN; Tannir NM; Matin SF; Wood CG
    Minerva Urol Nefrol; 2015 Jun; 67(2):149-56. PubMed ID: 25645343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Editorial Comment to Role of cytoreductive nephrectomy for Japanese patients with primary renal cell carcinoma in the cytokine and targeted therapy era.
    Bigot P; Lebdai S; Azzouzi AR
    Int J Urol; 2015 Aug; 22(8):740-1. PubMed ID: 26012629
    [No Abstract]   [Full Text] [Related]  

  • 12. Has the Age of Cytoreductive Nephrectomy Come to an End?: Commentary on: Sunitinib Alone or After Nephrectomy in Metastatic Renal-Cell Carcinoma.
    Kesch C; Black PC
    Urology; 2018 Nov; 121():1-2. PubMed ID: 30077538
    [No Abstract]   [Full Text] [Related]  

  • 13. Cytoreductive nephrectomy in metastatic renal cancer - less is more.
    Bex A; Haanen J
    Nat Rev Clin Oncol; 2018 Oct; 15(10):595-596. PubMed ID: 29967447
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: Craig Rogers, Ravi Barod, Scott Schwartz, Mani Menon. Endovascular Extraction of Caval Tumor Thrombus to Facilitate Minimally Invasive Cytoreductive Nephrectomy for Metastatic Kidney Cancer. Eur Urol 2015;68:167-8.
    Greco M; Butticè S; Magno C; Onida S
    Eur Urol; 2016 Aug; 70(2):e51-2. PubMed ID: 26850971
    [No Abstract]   [Full Text] [Related]  

  • 15. Sunitinib and Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma.
    Bajic P; Flanigan RC; Joyce CJ; Clark JI
    J Urol; 2019 Mar; 201(3):453-454. PubMed ID: 30266335
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus.
    Matveev VB; Volkova MI
    Eur Urol; 2017 Dec; 72(6):1024. PubMed ID: 28916409
    [No Abstract]   [Full Text] [Related]  

  • 17. Assessing the Contemporary Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Another Step in the Right Direction.
    Sun M; de Velasco G; Trinh QD; Choueiri TK
    Eur Urol; 2016 Jan; 69(1):92-3. PubMed ID: 26056068
    [No Abstract]   [Full Text] [Related]  

  • 18. [CYTOREDUCTIVE NEPHRECTOMY IN METASTATIC RENAL CELL CANCER].
    Nosov AK; Novik AV; Vorobiev AV; Samartseva EE; Reva SA; Baldueva IA; Lushina PA
    Vopr Onkol; 2015; 61(3):494-8. PubMed ID: 26242167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytoreductive nephrectomy for metastatic renal cell carcinoma.
    Chery LJ; Karam JA; Wood CG
    Clin Adv Hematol Oncol; 2016 Sep; 14(9):696-703. PubMed ID: 27673288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncological outcomes after cytoreductive nephrectomy for patients with metastatic renal cell carcinoma with inferior vena caval tumor thrombus.
    Miyake H; Sugiyama T; Aki R; Matsushita Y; Tamura K; Motoyama D; Ito T; Otsuka A
    Int J Clin Oncol; 2018 Jun; 23(3):553-558. PubMed ID: 29332206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.